Loading…
Attending this event?

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Monday, September 19
 

7:30am EDT

Welcome Breakfast
Sponsored by: 


Monday September 19, 2022 7:30am - 8:30am EDT

7:30am EDT

Registration
Monday September 19, 2022 7:30am - 5:30pm EDT

8:30am EDT

Chairperson’s Opening Remarks
Monday September 19, 2022 8:30am - 8:45am EDT

8:45am EDT

Keynote
Monday September 19, 2022 8:45am - 9:15am EDT

9:15am EDT

Partner Keynote: Fujifilm Diosynth Biotechnologies
Monday September 19, 2022 9:15am - 9:45am EDT

9:45am EDT

Panel: Battling Biotech’s Bear Market
There’s no doubt that biotech is facing tough times: shares are in freefall, investors have shut off the tap that flowed in the wake of the COVID crisis, clinical results are beginning to thin the good ideas from the bad and small companies are being forced to lay off staff. How can companies stay afloat, raise money and keep alive in this bear market?

Moderated by: Querida Anderson, Managing Editor, Fierce Biotech

Speakers
avatar for Querida Anderson

Querida Anderson

Managing Editor, Fierce Biotech
Querida Anderson is the managing editor for Fierce Biotech, Healthcare, Medtech and Pharma. Before joining Fierce in June 2021, she was the editor in chief of GlobalData’s investigative pharma news team, formerly known as BioPharm Insight when it was owned by the Financial Times... Read More →


Monday September 19, 2022 9:45am - 10:30am EDT

10:30am EDT

Networking Break
Monday September 19, 2022 10:30am - 11:00am EDT

11:00am EDT

Panel: The R&D Dilemma: Embracing New Modalities vs. Tried-and-True Approaches
The last few decades have seen the biotech industry lead the charge in R&D innovation. But as companies look for ways to differentiate their products, R&D efforts have shifted from small molecules to exploring more advanced therapies. Is this the right approach for every company? Developing a molecule that doesn’t progress as hoped can be make or break for a biotech and have a drastic impact on their ability to raise capital or find partners.  
  
This session will explore the pros and cons of sticking to an area of research that is tried and tested vs. embracing new modalities of treatment, and how to navigate the unique challenges of emerging modalities such as the ability to manufacture these treatments.

Monday September 19, 2022 11:00am - 11:45am EDT

11:45am EDT

Presentation
Monday September 19, 2022 11:45am - 12:15pm EDT

12:15pm EDT

Presentation
Monday September 19, 2022 12:15pm - 12:30pm EDT

12:30pm EDT

Networking Lunch
Sponsored by:


Monday September 19, 2022 12:30pm - 1:30pm EDT

1:30pm EDT

Fireside Chat/Executive Interview
Monday September 19, 2022 1:30pm - 2:00pm EDT

2:00pm EDT

Panel: Setting a Foundation for Success Through Innovative Clinical Trial Design
Clinical trials can often face delays if there are unexpected changes to the trial design or difficulty attracting qualified patients. The cost implications of pivoting can dramatically increase when it comes to Phase III trials, and it's imperative for companies to ensure they are picking the right design for their needs. This panel will discuss innovative approaches to design clinical trials, methods to integrate biomarkers, endpoint evaluation and exclusionary criteria to improve efficiency.

Speakers
avatar for José Trevejo, MD, PhD

José Trevejo, MD, PhD

Chief Medical Officer, Tarsus Pharmaceuticals, Inc.
José brings his experience and passion for leading research and development teams in the advancement of novel therapeutics for serious and rare diseases. Before joining Tarsus, José served as Chief Development Officer for Rocket Pharmaceuticals and CEO of the non-viral gene therapy... Read More →


Monday September 19, 2022 2:00pm - 2:45pm EDT

2:45pm EDT

Panel: Evaluate Innovative Deal Structures and How to Find the Right Partner
Speakers
avatar for Rachel Zolot Schwartz, MBA

Rachel Zolot Schwartz, MBA

VP, Head of Business Development and Commercial, Volastra Therapeutics
Rachel Zolot Schwartz is Head of Business Development & Commercial at Volastra Therapeutics, where she led the diligence, negotiation and contracting for the company’s first major pharma partnership, an up to $1.1B discovery deal with Bristol Myers Squibb. She has developed the... Read More →


Monday September 19, 2022 2:45pm - 3:30pm EDT

3:30pm EDT

Networking Break
Monday September 19, 2022 3:30pm - 4:00pm EDT

4:00pm EDT

Data Integrity and High-Velocity Biotech Business with Digital Twins
As fast-growing biotech organizations are pressed to accelerate research through clinical trials, modern technologies that create digital twins of the scientific process are needed to enable businesses to deliver faster results. Join Dr. Vasu Rangadass as he explores emerging digital technologies such as digital twins and pre-validated unified platforms that provide data integrity and increased velocity. Dr. Rangadass will also draw from recent case studies to illuminate these simplified information architectures that help correlate scientific processes to product and patient outcomes.

Speakers
avatar for Vasu Rangadass, PhD

Vasu Rangadass, PhD

President & CEO, L7 Informatics, Inc.
Vasu Rangadass, Ph.D., President and CEO at L7 Informatics, Inc., is a leader in enterprise-scale digital transformation and automation of scientific processes. Previously, Dr. Rangadass was the Chief Strategy Officer at NantHealth following its acquisition of Net.Orange, the company... Read More →


Monday September 19, 2022 4:00pm - 4:30pm EDT

4:30pm EDT

Panel: Fierce 15 - What does it mean to be Fierce?
In this panel, we check in with past Fierce 15 honorees to track their journeys from start-up to the big time. Where are they now, and where are they going?

Moderated by: Max Bayer, Staff Writer, Fierce Biotech

Speakers
avatar for Max Bayer

Max Bayer

Staff Writer, Fierce Biotech
Max Bayer is a staff writer for Fierce Biotech. He joined after more than three years at CBS News, two of which were spent covering the twists and turns of the COVID-19 pandemic, from infection trends to CDC guidelines. He graduated from the University of Wisconsin-Madison in 2018... Read More →
avatar for John Evans

John Evans

Chief Executive Officer and Board Member, Beam Therapeutics
John Evans joined Beam in 2017 as CEO, bringing significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry.Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, most recently serving as... Read More →
avatar for Fabrice Chouraqui

Fabrice Chouraqui

CEO, Cellarity
Fabrice Chouraqui, PharmD, joined Flagship Pioneering in 2020, where he serves as both CEO-Partner of Flagship Pioneering and CEO of Cellarity. Fabrice is an experienced global pharmaceutical executive with a passion for driving the progress of medical sciences and bringing innovation... Read More →
avatar for Thomas Schuetz

Thomas Schuetz

CEO, Compass Therapeutics
A senior biotechnology executive with Venture Capital, Board of Directors, and Management experience who has built fully functional clinical departments at both early and late-stage biotechnology companies.
avatar for Andrew Allen

Andrew Allen

CEO, Gritstone Bio


Monday September 19, 2022 4:30pm - 5:30pm EDT

5:30pm EDT

The Fierce Biotech Fierce 15 Awards + Reception
Join us as we unveil the top biotech innovators handpicked by Fierce Biotech editors and honored in-person during our cocktail reception.

Sponsored by: Fujifilm Diosynth Biotechnologies


Monday September 19, 2022 5:30pm - 6:30pm EDT

6:30pm EDT

Day One Concludes
Monday September 19, 2022 6:30pm - 6:30pm EDT
 
Tuesday, September 20
 

8:00am EDT

Networking Breakfast
Tuesday September 20, 2022 8:00am - 8:45am EDT

8:45am EDT

Keynote
Tuesday September 20, 2022 8:45am - 9:15am EDT

9:15am EDT

Partner Keynote
Tuesday September 20, 2022 9:15am - 9:45am EDT

9:45am EDT

Panel: Leverage AI and ML to Advance Discovery and Accelerate Drug Development
Developing a therapeutic on average takes 12+ years and billions of dollars, but now with AI and machine learning, the potential to identify molecules and bring them to the clinic faster and cheaper can be a reality. But where has there been proven success applying AI and ML and does it live up to the hype?

Speakers
avatar for Andrew A. Radin

Andrew A. Radin

Co-founder and CEO, Aria Pharmaceuticals
Andrew A. Radin is the co-founder and Chief Executive Officer of Aria Pharmaceuticals. Andrew created the company’s first drug development algorithms as part of his studies in biomedical informatics at Stanford University in 2014. Since co-founding Aria, Andrew was named an Emerging... Read More →
avatar for Molly Gibson, Ph.D

Molly Gibson, Ph.D

Co-founder, Chief Strategy and Chief Innovation Officer, Generate Biomedicines
Molly serves as co-founder and chief strategy and chief innovation officer of Generate Biomedicines, a Flagship Pioneering company. At Generate, she oversees corporate strategy, platform and data strategy, and an innovation group called G:Labs that explores novel applications of the... Read More →


Tuesday September 20, 2022 9:45am - 10:30am EDT

10:30am EDT

Networking Break
Tuesday September 20, 2022 10:30am - 11:00am EDT

11:00am EDT

Fireside Chat/Executive Interview 
Tuesday September 20, 2022 11:00am - 11:30am EDT

11:30am EDT

Presentation
Tuesday September 20, 2022 11:30am - 12:00pm EDT

12:00pm EDT

Networking Lunch
Tuesday September 20, 2022 12:00pm - 1:00pm EDT

1:00pm EDT

1:00pm EDT

1:15pm EDT

Keynote: Clinical Development
Tuesday September 20, 2022 1:15pm - 1:45pm EDT

1:15pm EDT

Keynote: Early-Stage Development
Tuesday September 20, 2022 1:15pm - 1:45pm EDT

1:45pm EDT

Panel: Clinical Development Topic
Tuesday September 20, 2022 1:45pm - 2:30pm EDT

1:45pm EDT

Panel: Gene Editing Therapies
It's been 10 years since Jennifer Doudna and Emmanuelle Charpentier’s Nobel Prize-winning discovery of the ability to edit genes using CRISPR. The publication of their paper set the biotech world aflame. So how is gene editing being applied to human medicine?

In this panel, we’ll hear from some of the leading biotechs at the forefront of bringing gene editing into the clinic—the promise, the challenges and the pitfalls of this emerging modality.

Moderated by: Angus Liu, Senior Writer, Fierce Biotech

Speakers
avatar for Angus Liu

Angus Liu

Senior Writer, Fierce Biotech
Angus is a senior staff writer with Questex’s Life Sciences group. He earned his Master’s at Northwestern University’s Medill School of Journalism, where he worked as a health reporter besides learning pertinent skills in magazine editing and interactive production. Prior to... Read More →
avatar for Craig Mickanin

Craig Mickanin

Executive Director in Chemical Biology and Therapeutics and global head of the Genomic Sciences Group, Novartis Institutes for BioMedical Research
Craig Mickanin is an executive director in Chemical Biology and Therapeutics and global head of the Genomic Sciences Group at the Novartis Institutes for BioMedical Research. He has been with Novartis for 24 years, most of which he has spent studying cell & gene therapies. In his... Read More →
avatar for David Lebwohl, M.D.

David Lebwohl, M.D.

Executive Vice President, Chief Medical Officer, Intellia Therapeutics, Inc.
Dr. David Lebwohl’s career spans three decades in the biopharmaceutical industry, successfully bringing novel medicines through all phases of clinical trials and global regulatory approvals. During his career, he has overseen multiple full-scale development programs with more than... Read More →
avatar for Giuseppe Ciaramella, Ph.D.

Giuseppe Ciaramella, Ph.D.

President and Chief Scientific Officer, Beam Therapeutics
Dr. Giuseppe Ciaramella is the President and Chief Scientific Officer of Beam Therapeutics. Dr. Ciaramella has more than 20 years of drug discovery experience at Moderna, AstraZeneca, Boehringer Ingelheim, Pfizer and Merck.Throughout his career he has held several leadership roles... Read More →


Tuesday September 20, 2022 1:45pm - 2:30pm EDT

2:30pm EDT

Presentation: Clinical Development
Tuesday September 20, 2022 2:30pm - 3:00pm EDT

2:30pm EDT

Presentation: Early-Stage Development
Tuesday September 20, 2022 2:30pm - 3:00pm EDT

3:00pm EDT

Panel: Clinical Development
Tuesday September 20, 2022 3:00pm - 3:45pm EDT

3:00pm EDT

Panel: Early-Stage Development
Tuesday September 20, 2022 3:00pm - 3:45pm EDT

3:45pm EDT

Chairperson’s Closing Remarks
Tuesday September 20, 2022 3:45pm - 4:00pm EDT

3:45pm EDT

Chairperson’s Closing Remarks
Tuesday September 20, 2022 3:45pm - 4:00pm EDT

4:00pm EDT

Conference Concludes
Tuesday September 20, 2022 4:00pm - 4:00pm EDT